What is HC Wainwright’s Estimate for ELVN Q1 Earnings?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Equities research analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Enliven Therapeutics in a report issued on Thursday, March 26th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.44) for the quarter, down from their prior estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $56.00 target price on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.00) EPS.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06).

Several other equities research analysts have also weighed in on ELVN. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Finally, Mizuho boosted their price target on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.40.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $38.83 on Monday. The firm has a market capitalization of $2.32 billion, a PE ratio of -20.88 and a beta of 0.33. Enliven Therapeutics has a 12-month low of $13.30 and a 12-month high of $40.62. The firm has a 50-day moving average price of $28.56 and a 200 day moving average price of $23.02.

Insider Activity

In other news, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This trade represents a 16.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Joseph P. Lyssikatos sold 91,198 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.22, for a total transaction of $2,482,409.56. Following the completion of the transaction, the insider owned 765,188 shares of the company’s stock, valued at $20,828,417.36. This trade represents a 10.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 232,180 shares of company stock valued at $6,217,033. Company insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ELVN. Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Swiss National Bank increased its stake in shares of Enliven Therapeutics by 1.7% in the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after buying an additional 1,100 shares in the last quarter. Finally, Quantbot Technologies LP increased its stake in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.